Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals

被引:106
|
作者
Vemuri, Prashanthi [1 ]
Knopman, David S. [2 ]
Lesnick, Timothy G. [3 ]
Przybelski, Scott A. [3 ]
Mielke, Michelle M. [3 ]
Graff-Radford, Jonathan [2 ]
Murray, Melissa E. [4 ]
Roberts, Rosebud O. [3 ]
Vassilaki, Maria [3 ]
Lowe, Val J. [1 ]
Machulda, Marym. [5 ]
Jones, David T. [2 ]
Petersen, Ronald C. [2 ]
Jack, Clifford R., Jr. [1 ]
机构
[1] Mayo Clin, Dept Radiol, Rochester, MN USA
[2] Mayo Clin, Dept Neurol, Rochester, MN USA
[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[4] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA
[5] Mayo Clin, Dept Psychol, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
MEDICAL-RECORDS-LINKAGE; MILD COGNITIVE IMPAIRMENT; VASCULAR RISK-FACTORS; APOLIPOPROTEIN-E; INTELLECTUAL ENRICHMENT; BRAIN ATROPHY; APOE ALLELE; DEMENTIA; EPIDEMIOLOGY; ASSOCIATION;
D O I
10.1001/jamaneurol.2017.0244
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IMPORTANCE While amyloid and neurodegeneration are viewed together as Alzheimer disease pathophysiology (ADP), the factors that influence amyloid and AD-pattern neurodegeneration may be considerably different. Protection from these ADP factors may be important for aging without significant ADP. OBJECTIVE To identify the combined and independent protective factors for amyloid and AD-pattern neurodegeneration in a population-based sample and to test the hypothesis that "exceptional agers" with advanced ages do not have significant ADP because they have protective factors for amyloid and neurodegeneration. DESIGN, SETTING, AND PARTICIPANTS This cohort study conducted a prospective analysis of 942 elderly individuals (70->= 90 years) with magnetic resonance imaging and Pittsburgh compound B-positron emission tomography scans enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study of cognitive aging in Olmsted County, Minnesota. We operationalized "exceptional aging" without ADP by considering individuals 85 years or older to be without significant evidence of ADP. MAIN OUTCOMES AND MEASURES We evaluated predictors including demographics, APOE, intellectual enrichment, midlife risk factors (physical inactivity, obesity, smoking, diabetes, hypertension, and dyslipidemia), and the total number of late-life cardiac and metabolic conditions. We used multivariate linear regression models to identify the combined and independent protective factors for amyloid and AD-pattern neurodegeneration. Using a subsample of the cohort 85 years of age or older, we computed Cohen d-based effect size estimations to compare the quantitative strength of each predictor variable in their contribution with exceptional aging without ADP. RESULTS The study participants included 423 (45%) women and the average age of participants was 79.7 (5.9) years. Apart from demographics and the APOE genotype, only midlife dyslipidemia was associated with amyloid deposition. Obesity, smoking, diabetes, hypertension, and cardiac and metabolic conditions, but not intellectual enrichment, were associated with greater AD-pattern neurodegeneration. In the 85 years or older cohort, the Cohen d results showed small to moderate effects (effect sizes > 0.2) of several variables except job score and midlife hypertension in predicting exceptional aging without ADP. CONCLUSIONS AND RELEVANCE The protective factors that influence amyloid and AD-pattern neurodegeneration are different. "Exceptional aging" without ADP may be possible with a greater number of protective factors across the lifespan but warrants further investigation.
引用
收藏
页码:718 / 726
页数:9
相关论文
共 50 条
  • [1] Alzheimer disease:: protective factors
    Nourhashémi, F
    Gillette-Guyonnet, S
    Andrieu, S
    Ghisolfi, A
    Ousset, PJ
    Grandjean, H
    Grand, A
    Pous, J
    Vellas, B
    Albarède, JL
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2000, 71 (02): : 643S - 649S
  • [2] Protective Factors Modulate the Risk of Beta Amyloid in Alzheimer's Disease
    Zhou, Bin
    Tanabe, Kenichiro
    Kojima, Shinsuke
    Teramukai, Satoshi
    Fukushima, Masanori
    BEHAVIOURAL NEUROLOGY, 2020, 2020
  • [3] Risk and protective factors for sporadic Alzheimer's disease
    Stozicka, Z.
    Zilka, N.
    Novak, M.
    ACTA VIROLOGICA, 2007, 51 (04) : 205 - 222
  • [4] DNAJ Proteins in neurodegeneration: essential and protective factors
    Zarouchlioti, Christina
    Parfitt, David A.
    Li, Wenwen
    Gittings, Lauren M.
    Cheetham, Michael E.
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2018, 372 (1738)
  • [5] Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals
    Sun, Qingling
    Ni, Jingnian
    Wei, Mingqing
    Long, Siwei
    Li, Ting
    Fan, Dongsheng
    Lu, Tao
    Shi, Jing
    Tian, Jinzhou
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [6] Alzheimer's disease: risk factors and potentially protective measures
    Ferreira Silva, Marcos Vinicius
    Gomide Loures, Cristina de Mello
    Vieira Alves, Luan Carlos
    de Souza, Leonardo Cruz
    Gomes Borges, Karina Braga
    Carvalho, Maria das Gracas
    JOURNAL OF BIOMEDICAL SCIENCE, 2019, 26 (1)
  • [7] Alzheimer’s disease: risk factors and potentially protective measures
    Marcos Vinícius Ferreira Silva
    Cristina de Mello Gomide Loures
    Luan Carlos Vieira Alves
    Leonardo Cruz de Souza
    Karina Braga Gomes Borges
    Maria das Graças Carvalho
    Journal of Biomedical Science, 26
  • [8] NEURODEGENERATION An Alzheimer's-disease-protective APOE mutation
    Zalocusky, Kelly A.
    Nelson, Maxine R.
    Huang, Yadong
    NATURE MEDICINE, 2019, 25 (11) : 1648 - 1649
  • [9] Apoptosis in Alzheimer's disease - Inductive agents and antioxidant protective factors
    Cotman, CW
    Pike, CJ
    PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES, 1998, 49 : 45 - 51
  • [10] Haploinsufficiency and Alzheimer's Disease: The Possible Pathogenic and Protective Genetic Factors
    Bagyinszky, Eva
    An, Seong Soo A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (22)